医药股Neumora重磅失利！抗忧郁疗法临床试验未达标，股价暴跌引市场关注
Neumora Therapeutics, Inc. 的主要抗忧郁药物navacaprant在第三期KOASTAL-1研究中未能达成预期目标，导致股价周四大跌81.42%。
Neumora Therapeutics于周四宣布，其针对主要忧郁症（MDD）的Phase 3 KOASTAL-1临床试验结果不尽如人意，未能达成主要终点。此讯息一出，华盛顿州的生技公司立即遭遇短暂的交易停牌，随后股价急剧下跌，周四收跌81.42%，引起投资者的广泛担忧。
该公司主打的药物navacaprant（NMRA-140）原本被寄予厚望，希望能为患者带来新的治疗选择。然而，最新的试验资料显示，这款药物并未有效改善受试者的病情，令市场信心受到重创。根据分析师的评估，此次失败可能会影响Neumora未来的研发计划与资金运作。
尽管有些专家认为此次失利是由于试验设计或样本量不足所致，但仍难以掩盖市场对其长期前景的疑虑。未来，Neumora需要重新评估其产品线及策略，以应对当前困境，并寻找其他潜在的成功路径。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10